Chyi-Liang Chen | Molecular epidemiology | Best Researcher Award

Published on by Academic Awards

Prof. Chyi-Liang Chen | Molecular epidemiology | Best Researcher Award

Prof. Chyi-Liang Chen, Linkou Chang Gung Memorial Hospital Children’s Medical Center, Taiwan

🧬 Prof. Chyi-Liang Chen is an Associate Researcher at Chang Gung Memorial Hospital and the Department of Microbiology and Immunology, Chang Gung University, Taiwan. He earned his BSc, MSc, and PhD in Life Sciences from National Chung Hsing University. With extensive postdoctoral research at Chang Gung University and the University of Calgary, his expertise spans microbiology, molecular microbiology, protein engineering, bacterial genomics, and antimicrobial resistance. He has authored numerous SCIE-indexed publications on bacterial pathogenesis and genetic engineering. His work contributes to biotechnology, genomics, and patent applications, advancing microbial research. πŸ¦ πŸ”¬πŸ“š

Publication Profile

Scopus

Orcid

πŸŽ“ Educational Background

Prof. Chyi-Liang Chen pursued his academic journey in Life Sciences at National Chung Hsing University, Taiwan. He obtained his Bachelor’s degree (1984–1988) from the Department of Life Sciences (formerly the Department of Botany). He then completed his Master’s degree (1988–1990) at the Institute of Life Sciences (previously the Institute of Botany Microbiome). Further advancing his expertise, he earned a Ph.D. (1990–1995) from the same institute. His strong foundation in microbiology, molecular biology, and botany has significantly contributed to his impactful research in bacterial genomics and biotechnology. πŸ§¬πŸ”¬πŸ“–

πŸ… Professional Experience

Prof. Chyi-Liang Chen has an extensive career in microbiology and immunology. He began as a Postdoctoral Fellow at Chang Gung University, Taiwan (1997–1999) before moving to the University of Calgary, Canada (1999–2002). He later returned to Chang Gung University (2002–2006). He served as an Assistant Professor at Yuanzhi University and later as an Assistant Researcher at Chang Gung Memorial Hospital (2006–2012). Since 2012, he has been an Associate Researcher at Chang Gung Memorial Hospital and, from 2022, also at the Department of Microbiology and Immunology, Chang Gung University. πŸ§ͺπŸ”¬πŸ“š

πŸ”¬ Research Focus

Prof. Chyi-Liang Chen specializes in infectious diseases, microbiology, and immunology. His research spans viral infections 🦠, antimicrobial resistance πŸ’Š, and host-pathogen interactions πŸ₯. He has contributed to studies on multiple viral infections in children, cytomegalovirus colitis, and antiviral treatments. His work also explores the gut microbiota’s role in cancer therapy and cross-species microRNAs. Additionally, he has investigated COVID-19 therapeutics 😷 and SARS-CoV-2 variants 🧬. His studies provide crucial insights into infectious disease management, making significant contributions to global health and microbiological research. πŸŒπŸ”

Publication Top Notes

1️⃣ Multiple viral infections and antimicrobial use in hospitalized children with respiratory illness during pandemic and early post-pandemic era, Taiwan πŸ¦ πŸ’Š (Heliyon, 2025)Β 
2️⃣ Identifying the function of novel cross-species microRNAs from the excretory-secretory products of Angiostrongylus cantonensis fifth-stage larvae 🧬🦠 (Journal of Microbiology, Immunology and Infection, 2025)Β 
3️⃣ Maternal Infections, Antibiotics, Steroid Use, and Diabetes Mellitus Increase Risk of Early-Onset Sepsis in Preterm Neonates 🀰🦠 (Pathogens, 2025)Β 
4️⃣ Adequate antiviral treatment lowers overall complications of cytomegalovirus colitis among inpatients with inflammatory bowel diseases πŸ’ŠπŸ¦  (BMC Infectious Diseases, 2024) – 2 citations
5️⃣ Gut microbiota and clinical response to immune checkpoint inhibitor therapy in patients with advanced cancer 🦠πŸ§ͺ (Biomedical Journal, 2024) – 5 citations
6️⃣ Antimicrobial activity of eravacycline and other comparative agents on aerobic and anaerobic bacterial pathogens in Taiwan πŸ’ŠπŸ¦  (Journal of Global Antimicrobial Resistance, 2024) – 1 citation
7️⃣ Complete genome sequence of Bacillus halotolerans F29-3, a fengycin-producing strain 🧬🦠 (Microbiology Resource Announcements, 2024)Β 
8️⃣ Cytomegalovirus Diseases of the Gastrointestinal Tract in Immunocompetent Patients: A Narrative Review πŸ¦ πŸ“– (Viruses, 2024) – 5 citations
9️⃣ Safety, tolerability, and efficacy of intranasally-administered detoxified LTh(Ξ±K) in mild-to-moderate COVID-19 patients πŸ’‰πŸ¦  (Human Vaccines and Immunotherapeutics, 2024)Β 
πŸ”Ÿ Worldwide SARS-CoV-2 Omicron variant infection: Emerging sub-variants and future vaccination perspectives πŸ¦ πŸ’‰ (Journal of the Formosan Medical Association, 2024) – 1 citation

Conclusion

Prof. Chyi-Liang Chen is highly suitable for the Best Researcher Award due to his strong academic background, international research experience, expertise in microbiology and bacterial pathogenesis, and high-impact publications. His work has significantly advanced molecular microbiology and biotechnology, making him a worthy candidate for this prestigious recognition.

Asal Katebi | Infectious disease | Best Researcher Award

Published on by Academic Awards

Dr. Asal Katebi | Infectious disease | Best Researcher Award

Medical Immunology, Pasteur Institute of Iran

Asal Katebi, Ph.D., is an Assistant Professor at the Pasteur Institute of Iran, specializing in Medical Immunology. Her research focuses on developing therapeutic vaccines for infectious diseases like leishmaniasis using nanoparticle formulations and TLR agonists. She holds a Ph.D. in Medical Immunology from Isfahan University of Medical Sciences and has extensive experience in molecular biology and immunotherapy.

Profile

Google Scholar

 

πŸ“š Education:

Asal Katebi completed her Ph.D. in Medical Immunology at Isfahan University of Medical Sciences, where she conducted research on therapeutic vaccines for leishmaniasis. She also holds an M.Sc. in Medical Immunology from Tehran University of Medical Sciences and a B.Sc. in Microbiology from Islamic Azad University, North Tehran Branch.

πŸ‘©β€πŸ’Ό Experience:

Dr. Katebi’s professional journey includes significant roles at the Pasteur Institute of Iran, where she conducts research, mentors students, and teaches courses in immunology. She has expertise in molecular immunology, nanoparticle preparation, cell culture techniques, and has contributed to numerous research projects aimed at combating infectious diseases.

πŸ”¬ Research Interests:

Her research interests span molecular immunology and immunotherapy, focusing on vaccine development against leishmaniasis. Dr. Katebi is particularly interested in nanoparticle-based delivery systems, TLR agonists, and the immunomodulatory effects of extracellular vesicles derived from parasites.

πŸ† Awards:

Asal Katebi has received recognition for her contributions to immunological research, including awards for her presentations at international congresses. Notably, she was honored for her work on the SLA-R848-Pam3CSK4 combination as a therapeutic vaccine for cutaneous leishmaniasis.

πŸ“„ Publications:

Leishmania tarentolae secreting the sand fly salivary antigen PpSP15 confers protection against Leishmania major infection – Molecular Immunology, 2015

Leishmania tarentolae secreting PpSP15 and CpG motifs protects against Leishmania major infection – European Journal of Immunology, 2019

Combinatorial delivery of antigen and TLR agonists via PLGA nanoparticles modulates Leishmania major-infected macrophages – Biomedicine & Pharmacotherapy, 2021